TITLE

Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug

AUTHOR(S)
Youngjoo Lee; Hyae Young Kim; Soo-Hyun Lee; Kun Young Lim; Geon Kook Lee; Tak Yun; Ji-Youn Han; Heung Tae Kim; Jin Soo Lee
PUB. DATE
March 2014
SOURCE
Clinical Lung Cancer;Mar2014, Vol. 15 Issue 2, p145
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
94754949

 

Related Articles

  • Defining clinically relevant molecular subsets of lung cancer. Pao, William // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p11 

    The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, induce dramatic responses in certain patients with non-small cell lung cancer (NSCLC). As such, the drugs provide an unexpected tool to dissect clinically relevant molecular subsets of NSCLC....

  • Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report. QIONG SUN; JIAN-YU WU; SHUN-CHANG JIAO // Oncology Letters;2014, Vol. 8 Issue 5, p2093 

    Lung cancer is a heterogeneous and complex disease that remains the leading cause of cancer-related mortality worldwide. The identification of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangements has changed the treatment of non-small cell lung...

  • Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Xinghua Cheng; Haiquan Chen // OncoTargets & Therapy;2014, Vol. 7, p1689 

    Lung cancer, mostly nonsmall cell lung cancer, continues to be the leading cause of cancer-related death worldwide. With the development of tyrosine kinase inhibitors that selectively target lung cancer-related epidermal growth factor receptor mutations, management of advanced nonsmall cell lung...

  • Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Krawczyk, Paweł; Mlak, Radosław; Powrózek, Tomasz; Nicoś, Marcin; Kowalski, Dariusz M.; Wojas-Krawczyk, Kamila; Milanowski, Janusz // Contemporary Oncology / Wspolczesna Onkologia;2012, Vol. 16 Issue 5, p401 

    Abnormalities of epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) patients consist of EGFR overexpression and EGFR (HER1) gene mutations. Structural dysfunction of the tyrosine kinase domain of EGFR is associated with the clinical response to tyrosine kinase...

  • Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer. Kosaka, Takayuki; Yamaki, Ei; Mogi, Akira; Kuwano, Hiroyuki // Journal of Biomedicine & Biotechnology;2011, p1 

    Gefitinib and erlotinib, which are epidermal growth factor receptor- (EGFR-) specific tyrosine kinase inhibitors (TKIs), are widely used as molecularly targeted drugs for non-small-cell lung cancer (NSCLC). Currently, the search for EGFR gene mutations is becoming essential for the treatment of...

  • Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. Spaans, Johanna N.; Goss, Glenwood D. // Frontiers in Oncology;Jul2014, Vol. 4, p1 

    Our ability to detect and directly target the oncogenic alterations responsible for tumor proliferation has contributed significantly to the management of lung cancer in the last decade. The therapeutic efficacy of molecularly targeted therapy is, however, mainly limited to patients harboring...

  • Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report. Sayaka Ohara; Tomonori Ushijima; Mariko Gunji; Chiharu Tanai; Yoshiaki Tanaka; Hiromichi Noda; Hajime Horiuchi; Kazuhiro Usui // Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p1 

    Introduction Non-small-cell lung cancer harboring an activated epidermal growth factor receptor mutation exhibits a good response to epidermal growth factor receptor-tyrosine kinase inhibitors; however, clinicians often experience treatment failure following the development of resistance to...

  • MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. Presutti, Dario; Santini, Simonetta; Cardinali, Beatrice; Papoff, Giuliana; Lalli, Cristiana; Samperna, Simone; Fustaino, Valentina; Giannini, Giuseppe; Ruberti, Giovina // PLoS ONE;11/18/2015, Vol. 10 Issue 11, p1 

    Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor receptor (HER) family, plays a critical role in regulating multiple cellular processes including proliferation, differentiation, cell migration and cell survival. Deregulation of the EGFR signaling has been...

  • Lung Cancer Genotype-Based Therapy and Predictive Biomarkers. Cagle, Philip T.; Allen, Timothy Craig // Archives of Pathology & Laboratory Medicine;Dec2012, Vol. 136 Issue 12, p1482 

    Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted...

  • Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Berardi, Rossana; Santoni, Matteo; Morgese, Francesca; Ballatore, Zelmira; Savini, Agnese; Onofri, Azzurra; Mazzanti, Paola; Pistelli, Mirco; Pierantoni, Chiara; De Lisa, Mariagrazia; Caramanti, Miriam; Pagliaretta, Silvia; Pellei, Chiara; Cascinu, Stefano // OncoTargets & Therapy;2013, Vol. 6, p563 

    In the last decade, better understanding of the role of epidermal growth factor receptor in the pathogenesis and progression of non-small cell lung cancer has led to a revolution in the work-up of these neoplasms. Tyrosine kinase inhibitors, such as erlotinib and gefitinib, have been approved...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics